FiercePharmaOriginal article
{"a":[{"_":"Attruby cruises toward blockbuster land as BridgeBio CEO spots ‘stabilizer-first’ ATTR market","$":{"href":"/pharma/attruby-cruises-toward-blockbuster-land-bridgebio-ceo-spots-stabilizer-first-attr-market","hreflang":"en"}}]}
AttrubyPositive
AI Analysis
Summary
BridgeBio's Attruby is advancing toward blockbuster status as the company targets first-line ATTR-CM patients, directly competing with Alnylam in the stabilizer-vs-silencer treatment debate for this patient population.
Importance:6/10
Sentiment:
0.60
ATTR-CMstabilizersilencerfirst-line treatmentcompetitive landscapeQ2 earnings
Related Companies
Read the original article
Published by FiercePharma on August 11, 2026 11:01 AM